IL126158A0 - Method for treating substance abuse - Google Patents
Method for treating substance abuseInfo
- Publication number
- IL126158A0 IL126158A0 IL12615897A IL12615897A IL126158A0 IL 126158 A0 IL126158 A0 IL 126158A0 IL 12615897 A IL12615897 A IL 12615897A IL 12615897 A IL12615897 A IL 12615897A IL 126158 A0 IL126158 A0 IL 126158A0
- Authority
- IL
- Israel
- Prior art keywords
- substance abuse
- treating substance
- treating
- olanzapine
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Disintegrating Or Milling (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1316196P | 1996-03-11 | 1996-03-11 | |
US1316096P | 1996-03-11 | 1996-03-11 | |
GBGB9606615.4A GB9606615D0 (en) | 1996-03-29 | 1996-03-29 | Method for treating alcohol addiction |
GBGB9606617.0A GB9606617D0 (en) | 1996-03-29 | 1996-03-29 | Method for treating substance abuse |
PCT/US1997/003404 WO1997033586A1 (en) | 1996-03-11 | 1997-03-10 | Method for treating substance abuse |
Publications (1)
Publication Number | Publication Date |
---|---|
IL126158A0 true IL126158A0 (en) | 1999-05-09 |
Family
ID=27451428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12615897A IL126158A0 (en) | 1996-03-11 | 1997-03-10 | Method for treating substance abuse |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1007050B1 (xx) |
JP (1) | JP2000517287A (xx) |
KR (1) | KR19990087714A (xx) |
CN (1) | CN1213308A (xx) |
AT (1) | ATE295731T1 (xx) |
BR (1) | BR9708037A (xx) |
CA (1) | CA2248738A1 (xx) |
CZ (1) | CZ290398A3 (xx) |
DE (1) | DE69733321D1 (xx) |
IL (1) | IL126158A0 (xx) |
NO (1) | NO984196L (xx) |
NZ (1) | NZ331845A (xx) |
PL (1) | PL328924A1 (xx) |
TR (1) | TR199801801T2 (xx) |
WO (1) | WO1997033586A1 (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE253364T1 (de) * | 1998-11-23 | 2003-11-15 | Sepracor Inc | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen |
AU757874B2 (en) | 1998-11-23 | 2003-03-06 | Sepracor, Inc. | 2-hydroxymethylolanzapine compositions and methods |
PT1133300E (pt) | 1998-11-23 | 2005-04-29 | Sepracor Inc | Composicoes de desmetilolanzapina e metodos |
JP2004523513A (ja) * | 2001-01-12 | 2004-08-05 | イノベーション・ベンチャーズ・エルエルシー | 活性化木炭に基づく組成物及びアルコール含有飲料の消費に関連する二日酔いを低減するための方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5605911A (en) * | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US5696115A (en) * | 1995-04-21 | 1997-12-09 | Eli Lilly And Company | Method for treating nicotine withdrawal |
-
1997
- 1997-03-10 JP JP09522340A patent/JP2000517287A/ja not_active Withdrawn
- 1997-03-10 WO PCT/US1997/003404 patent/WO1997033586A1/en active IP Right Grant
- 1997-03-10 KR KR1019980707181A patent/KR19990087714A/ko not_active Application Discontinuation
- 1997-03-10 IL IL12615897A patent/IL126158A0/xx unknown
- 1997-03-10 CZ CZ982903A patent/CZ290398A3/cs unknown
- 1997-03-10 CN CN97193069A patent/CN1213308A/zh active Pending
- 1997-03-10 TR TR1998/01801T patent/TR199801801T2/xx unknown
- 1997-03-10 BR BR9708037A patent/BR9708037A/pt not_active Application Discontinuation
- 1997-03-10 NZ NZ331845A patent/NZ331845A/xx unknown
- 1997-03-10 AT AT97908871T patent/ATE295731T1/de not_active IP Right Cessation
- 1997-03-10 EP EP97908871A patent/EP1007050B1/en not_active Expired - Lifetime
- 1997-03-10 DE DE69733321T patent/DE69733321D1/de not_active Expired - Lifetime
- 1997-03-10 PL PL97328924A patent/PL328924A1/xx unknown
- 1997-03-10 CA CA002248738A patent/CA2248738A1/en not_active Abandoned
-
1998
- 1998-09-11 NO NO984196A patent/NO984196L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1213308A (zh) | 1999-04-07 |
TR199801801T2 (xx) | 1998-12-21 |
EP1007050B1 (en) | 2005-05-18 |
WO1997033586A1 (en) | 1997-09-18 |
KR19990087714A (ko) | 1999-12-27 |
BR9708037A (pt) | 1999-07-27 |
NO984196L (no) | 1998-11-03 |
AU2067297A (en) | 1997-10-01 |
JP2000517287A (ja) | 2000-12-26 |
NZ331845A (en) | 2000-09-29 |
AU725940B2 (en) | 2000-10-26 |
EP1007050A4 (en) | 2000-06-14 |
EP1007050A1 (en) | 2000-06-14 |
CZ290398A3 (cs) | 1999-10-13 |
ATE295731T1 (de) | 2005-06-15 |
CA2248738A1 (en) | 1997-09-18 |
NO984196D0 (no) | 1998-09-11 |
DE69733321D1 (de) | 2005-06-23 |
PL328924A1 (en) | 1999-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
GB9504216D0 (en) | Magnetic stimulator for neuro-muscular tissue | |
HK1010484A1 (en) | Pharmaceutical composition for use in treatment ofdiabetes. | |
SG99279A1 (en) | Myoblast therapy for cosmetic treatment | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
GB2298370B (en) | Magnetic stimulator for neuro-muscular tissue | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
EP0921803A4 (en) | METHOD FOR PREVENTING AND TREATING PESTVIRUS INFECTIONS AND RELATED DISEASES | |
IL126158A0 (en) | Method for treating substance abuse | |
IL126161A0 (en) | Method for treating autism | |
EP0828507A4 (en) | METHOD FOR TREATING PAIN | |
IL126157A0 (en) | Method for treating excessive aggression | |
AU5434899A (en) | Cancer treatment | |
EA199800820A1 (ru) | Способ лечения злоупотребления лекарственными средствами | |
EA199800818A1 (ru) | Способ лечения бессонницы | |
YU40198A (sh) | Postupak za tretiranje zavisnosti od supstance | |
AU6955998A (en) | Method for providing neuro-protective effects | |
ZA977873B (en) | Dosage form and method for administering drug. | |
HU9402028D0 (en) | Creme for treating feet of patients in diabetes | |
BG98003U (en) | Medicament for the treatment of dermatomycosis | |
TW352510U (en) | Panties used for old person or patient | |
IL107015A0 (en) | Method for treatment of blood | |
IL107586A0 (en) | Method for treatment of blood | |
HU9500691D0 (en) | Method for making resonator kozmovit and its application in alternative medical treatment |